

Factors associated with non-use of ART among men living with HIV in South Africa: findings from a population-based household survey

Nuha Naqvi^{1*}, Xan Swart², Jeremiah Chikovore³, Kassahun Ayalew¹, Sizulu Moyo^{4,5}, Diane Morof^{6,7}, David Makapela¹, Jason Bedford¹

¹Centers for Disease Control and Prevention, Pretoria, South Africa

²Stellenbosch University, Stellenbosch, South Africa

³Human Sciences Research Council, Durban, South Africa

⁴Human Sciences Research Council, Cape Town, South Africa

⁵School of Public Health and Family Medicine, University of Cape Town, South Africa

⁶Centers for Disease Control and Prevention, Durban, South Africa

⁷U.S. Public Health Service Commissioned Corps, Rockville, Maryland, United States

*Corresponding author: Nuha Naqvi

Email: qnh2@cdc.gov

1 **Abstract**

2 **Introduction:** Although South Africa adopted the World Health Organization's Test and Treat strategy
3 for HIV epidemic control in 2016, antiretroviral therapy (ART) treatment initiation and retention remain
4 below target. In 2017, an estimated 56.3% of men living with HIV were on ART. We aimed to investigate
5 factors associated with non-use of ART among men in South Africa.

6 **Methods:** Utilizing data from the fifth South African National HIV Prevalence, Incidence, Behavior and
7 Communication (SABSSM V) cross-sectional survey conducted in 2017, a subset of data from HIV-
8 positive men was stratified based on presence/absence of antiretroviral drugs (ARVs) detected in dried
9 blood spot samples. Data were weighted to be representative of the national population and analyzed
10 using multivariable logistic regression to assess predictors of non-use of ART; $p < 0.05$ was considered
11 significant.

12 **Results:** A total of 6,920 men aged ≥ 15 years old were enrolled in the study, of whom 953 (13.8%) tested
13 HIV-positive. Among those HIV-positive, 810 (85%) had a known ARV test result: 470 (58%) had ARVs
14 detected, and 340 (42%) did not have ARVs detected. Non-use of ART in men was associated with high-
15 risk alcohol use (adjusted odds ratio (AOR)=3.68, 95% confidence interval (CI): 1.03-13.23), being a
16 widower compared to being unmarried (AOR=6.99, 95%CI: 1.46-33.42), and having drug-resistant HIV
17 (AOR=28.12, 95%CI: 13.89-56.94). Per year increase in age (AOR=0.67, 95%CI: 0.47-0.96), residence
18 in rural tribal localities compared to urban localities (AOR=0.38, 95%CI: 0.18-0.78), or having a co-
19 morbidity such as tuberculosis or diabetes (AOR=0.06, 95%CI: 0.03-0.14) were positively associated
20 with ART use.

21 **Conclusions:** Non-use of ART was strongly associated with HIV drug resistance. Young men who are
22 living with HIV, those with high-risk alcohol use, and widowers, should be a priority for HIV
23 programming and linkage to care. Identifying interventions that are effective at linking these men to ART
24 will help reduce the burden of HIV in South Africa.

25

26 **Introduction**

27 Despite notable gains made in recent years to curb new infections, South Africa continues to battle the
28 world’s largest HIV epidemic. Although South Africa adopted the World Health Organization’s Test-and-
29 Treat strategy for HIV epidemic control in 2016 to make antiretroviral therapy (ART) more accessible
30 and available at no cost in the public sector, treatment initiation and retention remain below target. Poor
31 retention and non-ART use increases the risk of suboptimal viral suppression, and consequently the
32 likelihood of further transmission of HIV, drug resistance, treatment failure, associated morbidity and
33 mortality.

34 The fifth South Africa National HIV Prevalence, Incidence, Behavior and Communication (SABSSM V)
35 survey, conducted in 2017 found that 56.3% and 65.5% of men and women living with HIV, respectively,
36 were on ART [1]. The revised Joint United Nations Programme on HIV/AIDS (UNAIDS) Fast-Track 95–
37 95–95 targets aim to ensure that 95% of people living with HIV (PLHIV) are tested and diagnosed, 95%
38 of people diagnosed with HIV are receiving treatment, and 95% of people on treatment have a suppressed
39 viral load. By 2019, estimates indicated that in South Africa, 90% of people were aware of their HIV
40 status while only 68% of those diagnosed with HIV were on ART [2]. In 2021, ART coverage was
41 estimated at only 61.9% among males and 72.3% among females aged 15 years and older [3].

42 Across sub-Saharan Africa, men test for HIV at lower rates, have higher rates of attrition from treatment
43 programs, higher rates of virologic failure on ART, and higher mortality on ART [4]. Men are generally
44 less likely to engage and remain in care compared to women [5-7], and are more likely to experience a
45 deterioration in health after an HIV diagnosis [8]. Traditional requirements of men’s employment and
46 livelihoods tend to contribute to sub-optimal testing and engagement in treatment. A feeling of shame for
47 appearing “weak” is a well-documented deterrent for men when accessing treatment and healthcare
48 services [9]. Many men also fear being held responsible for transmitting HIV to their female sexual
49 partners, experiencing discomfort or embarrassment at being seen in health spaces that are considered

50 feminised spaces, and fear that engaging in care threatens their social standing and ability to socialise or
51 engage in work [10]. Entrenched gender norms promulgating the view that care-seeking and healthcare
52 spaces are primarily the woman's domain, contribute to an avoidance of HIV treatment among men. In
53 addition to stigma related to seeking healthcare, higher rates of alcohol and substance use among men are
54 also determinants of poor adherence to ART [11-12].

55 It is increasingly clear that strategies to improve access to care and health outcomes among men living
56 with HIV are essential to reach the UNAIDS 95-95-95 targets by 2030. The objective of this analysis is to
57 investigate factors associated with non-use of ART among men in South Africa. We describe uptake of
58 ART uptake among men who tested HIV-positive in the 2017 SABSSM V survey, and explore barriers
59 associated with effective linkage to HIV care and treatment for men.

60

61 **Methods**

62 The data used in this paper were obtained from SABSSM V, a cross-sectional, population-based
63 household HIV survey conducted in 2017 in South Africa. The multistage stratified random cluster
64 sampling approach of the survey is fully described elsewhere [1]. In summary, 1,000 small area layers
65 (SALs) were selected and stratified by province, locality type, and race groups to be nationally
66 representative. A maximum of 15 households/visiting points were randomly selected from each SAL. All
67 household members who slept in the selected household the previous night were eligible to participate.
68 After obtaining consent, household level data were collected through a questionnaire administered to the
69 head of the household. Thereafter, individual consent was obtained and an individual questionnaire that
70 collected sociodemographic information, knowledge and attitudes about HIV, and sexual behavior data
71 was administered. Adults aged 18 years or older signed informed consent forms, while parental/legal
72 guardian consent and individual assent were obtained for those aged 15-17 years old. The survey

73 questionnaires were captured electronically on a Mercer A105 tablet utilizing Census and Survey
74 Processing System (CSPPro) software.

75 Dried blood spot (DBS) specimens were collected by finger prick to test for HIV status, viral load (VL),
76 HIV recency using the limiting-antigen (LAg) avidity enzyme immunoassay (EIA), HIV drug resistance
77 (HIVDR), and detection of antiretroviral drugs (ARVs) from consenting participants. HIV antibody status
78 was determined using an algorithm with two different EIAs and a nucleic acid amplification test (NAAT)
79 for validating all positive results. VL testing used the Abbott platform (Abbott m2000 HIV Real-Time
80 System, Abbott Molecular Inc., Des Plaines, IL, USA). Samples with VL >1,000 copies/mL were
81 classified as virally unsuppressed and were submitted for HIVDR testing. HIVDR testing was conducted
82 by Next Generation Sequencing (NGS). Detection of ARVs in DBS samples was done by high-
83 performance liquid chromatography (HPCL) coupled with Tandem Mass Spectrometry. The testing panel
84 focused on drugs used in the public sector programme, and was set to detect Nevirapine, Efavirenz,
85 Lopinavir, Atazanavir and Darunavir. The detection limit was set at 0.02 µg/mL for each drug, with a
86 signal-to-noise ratio of at least 5:1.

87 The Human Sciences Research Council Research Ethics Committee provided ethical approval for the
88 survey (REC 4/18/11/15). This project was reviewed in accordance with Centers for Disease Control and
89 Prevention (CDC) human research protection procedures and was determined to be research, but CDC
90 investigators did not interact with study participants or have access to identifiable data or specimens for
91 research purposes. Personal identifiable information was not collected in the survey and confidentiality
92 was maintained during data collection, storage, analysis, and reporting.

93 For this analysis, a sub-sample comprised of HIV-positive male participants ≥ 15 years of age was
94 extracted. Female participants, male participants <15 years of age, and those who tested HIV-negative at
95 the time of the survey were excluded from this analysis. The outcome of interest was ARV use – those in
96 whom *ARVs were detected* (one or more of the five drugs in the testing panel) and those in whom *ARVs*
97 *were undetected*, representing males who were currently taking ARVs and males who were not (the latter

98 includes both those that were ART non-adherent and those that had never initiated ART) at the time of
99 sample collection. Figure 1 shows a flow diagram of study participants included in this analysis.

100 **Figure 1: Study Sample Flow Diagram, SABBSM V survey, 2017**

101

102 ***Variables***

103 In this analysis, ART use is defined based on the detection of any ARVs in blood specimens. Although
104 ART adherence was verbally volunteered by participants, these data were not used in this analysis due to
105 possible social desirability bias (being non-adherent is seen as a less desirable trait) and the authors opted
106 for a more robust observation of ART use.

107 Probing factors associated with ART non-use in South African HIV-positive males followed a multi-
108 faceted approach. Behavioral and demographic variables with known relationships to ART uptake and
109 other variables that were significant in the univariate analysis were then built into a logistic regression
110 model. Multi-level nominal variables with small samples were merged into variable categories for concise
111 analysis. Employment status, for example, originally consisted of five categories including 1)
112 unemployed, 2) sick/disabled and unable to work, 3) student/pupil, 4) employed/self-employed, and 5)
113 other. This was reduced to *employed* or *unemployed* groupings, which aided in generating relatively stable
114 estimates in the regression analysis. This reduction approach was used for level of education, main source
115 of healthcare, number of comorbidities, history of drug use, and number of life-time sexual partners.

116 Participants who scored 16 or more on the Alcohol Use Disorders Identification Test (AUDIT) [13] tool
117 were labelled as high risk for alcohol abuse/addiction in this study.

118 ***Analysis***

119 All statistical analyses were conducted using STATA software version 14.0 (Stata Corporation, College
120 Station, TX, United States) and RStudio 4.1.2 [14] using the survey package 4.0 [15], with data weighted
121 to be representative of the national population by sex, age, and race for 2017 as provided by the SABSSM
122 V survey. Exploratory analysis of factors assessed the variables' respective distributions followed by

123 appropriate hypothesis tests (student's t-test, chi-squared, Wilcoxon Rank-Sum tests) to test for
124 statistically significant differences between the detected and undetected ARV groups. Missing values
125 were excluded and $p < 0.05$ was considered significant.

126 Univariate logistic regression was used to analyze the strength of associations between individual
127 predictor variables and outcome variables, reported as odds ratios (ORs). A multivariable logistic
128 regression model including all relevant behavioral and sociodemographic variables was constructed to
129 measure the net effect of predictor variables on the outcome of ART non-use. Continuous independent
130 variables were standardized and centered at their respective means. Assessment of model fit parameters
131 (Akaike Information Criterion (AIC), pseudo- R^2) and level of missingness in certain factors guided the
132 construction of a final reduced multivariable logistic regression model, the results of which, are reported
133 as adjusted odds ratios (AORs) and 95% confidence intervals (CIs).

134

135 **Results**

136 A total of 6,920 men aged ≥ 15 years were enrolled in the study, of whom 953 (13.8%) had a laboratory
137 confirmed HIV-positive result. Among those HIV-positive, 810 (85.0%) had a known ARV test result:
138 470 (58%) had ARVs detected, and 340 (42%) did not have ARVs detected. Table 1 shows the
139 unweighted frequencies and weighted proportions of sociodemographic, behavioral, and clinical
140 characteristics of participants by ARV status. The mean age of the total study population was 38 years
141 old, lower among the ARV-undetected group (mean age of 34 years old) than the ARV-detected group
142 (mean age of 41 years old). Most participants identified as Black African (93.9%) and resided in urban
143 areas (67.4%). More than one quarter (29%) graduated from high school/finished matric and
144 approximately half were unemployed (50.6%). Most participants reported never being married (69.1%); a
145 greater proportion of those in the ARV-undetected group (74.7%) reported never being married as
146 compared to the ARV-detected group (64.5%).

147 **Table 1. Sociodemographic and behavioral characteristics of HIV-positive men aged ≥15 years by**
 148 **ARV status, 2017 SABSSM V survey.**

	Overall (N=810)	ARVs detected (n=470)	ARVs undetected (n=340)
	<i>Mean (SD)</i>	<i>Mean (SD)</i>	<i>Mean (SD)</i>
Age (years)	38 (11.05)	41 (11.47)	34 (9.25)
	<i>N (weighted %)</i>	<i>n (weighted %)</i>	<i>n (weighted %)</i>
Locality type			
Urban	441 (67.4)	243 (63.3)	198 (72.4)
Tribal Rural	269 (26.6)	181 (32.1)	88 (19.9)
Farm Rural	100 (6.0)	46 (4.6)	54 (7.7)
Race			
Black African	654 (93.9)	382 (94.2)	272 (93.5)
Coloured	55 (4.4)	26 (3.3)	29 (5.7)
Indian/White	30 (1.7)	18 (2.5)	12 (0.8)
Marital Status			
Married	176 (24.5)	113 (28.0)	63 (20.3)
Never Married	542 (69.1)	301 (64.5)	241 (74.7)
Divorced / separated	25 (3.3)	19 (4.4)	6 (1.9)
Widower	28 (3.1)	16 (3.2)	12 (3.1)
Employment Status = Unemployed	426 (50.6)	277 (57.2)	149 (42.6)
Level of Education Achieved			
No Education	65 (6.8)	43 (8.1)	22 (5.3)
Completed Primary School	182 (19.0)	118 (21.8)	64 (15.7)
Completed Grade 8-11	330 (44.4)	185 (44.1)	145 (44.8)
Completed Matric or Higher Education	193 (29.7)	102 (26.0)	91 (34.2)
Perception of own health			
Excellent	166 (21.6)	90 (19.2)	76 (24.6)
Good	400 (55.5)	218 (51.1)	182 (61.0)
Fair	159 (17.6)	108 (23.1)	51 (10.8)
Poor	43 (5.3)	31 (6.6)	12 (3.6)
Time since last visit to health facility			
Within the past six months	415 (55.3)	292 (66.1)	123 (42.0)
More than six months but not more than a year ago	105 (12.1)	55 (10.4)	50 (14.2)
More than one year ago	172 (22.8)	69 (15.6)	103 (31.6)
Never	75 (9.8)	30 (7.9)	45 (12.3)
Main source of healthcare			
Government	677 (85.3)	406 (86.7)	271 (83.6)
Private	74 (11.4)	37 (11.4)	37 (11.4)
Other	15 (3.3)	3 (1.9)	12 (5.1)
Previous TB diagnosis = No	620 (82.2)	325 (73.0)	295 (93.5)
Yes	190 (17.8)	145 (17.0)	45 (6.5)
Comorbidities			
No comorbidities	495 (64.0)	208 (45.9)	287 (86.4)
One Comorbidity	243 (28.2)	201 (41.6)	42 (11.5)
Two or More Comorbidities	72 (7.8)	61 (12.4)	11 (2.0)
Presence of a disability: Yes	43 (4.5)	32 (6.8)	11 (1.6)
History of drug use = Yes	146 (22.5)	78 (24.3)	68 (20.1)
High probability of alcohol abuse = Yes	46 (6.8)	23 (5.5)	23 (8.4)
High risk alcohol use score (mean (SD))	3.44 (6.40)	2.88 (5.81)	4.22 (7.01)

HIV drug resistance = Yes	332 (50.5)	83 (22.6)	249 (83.6)
Number of lifetime sexual partners			
Zero/one partner	81 (13.2)	44 (12.9)	37 (13.7)
Two-Three Partner	116 (15.5)	66 (14.6)	50 (16.7)
More than three partner	389 (71.3)	235 (72.5)	154 (69.6)
Previous sexually transmitted infection	49 (9.6)	27 (8.2)	22 (11.2)
Demonstrated understanding of HIV prevention = Yes	467 (62.3)	279 (61.6)	188 (63.1)
Demonstrated understanding of HIV treatment = Yes	571 (79.3)	359 (87.3)	212 (69.3)
Stigma towards HIV positive individuals = Yes	334 (40.2)	178 (38.9)	156 (41.7)
Has a mental illness or exhibits mental distress = Present	329 (43.1)	192 (43.3)	137 (42.8)

149 Table 1 includes the unweighted frequencies (N/n) and weighted proportions (%) of sociodemographic, behavioral, and clinical
150 characteristics of participants by ARV status.

151 Abbreviations: ART – Antiretroviral therapy; SABSSM – South Africa National HIV Prevalence, Incidence, Behavior and
152 Communication survey; SD – standard deviation; TB – tuberculosis.

153
154 Table 2 displays the univariate and multivariable logistic regression models of factors associated with
155 non-use of ART. In observing the univariate model, being employed was found to be a predictor of ART
156 use compared to those who are unemployed (odds ratio (OR)=0.56, 95%CI: 0.37-0.83, p<0.001). A
157 demonstrated understanding of HIV treatment was found to be associated with a decreased likelihood of
158 ART non-use (OR=0.33, 95%CI: 0.19-0.56, p<0.001). Presence of a disability decreased the likelihood of
159 ART non-use among men compared to the absence of disability (OR=0.22, 95%CI: 0.07-0.68, p=0.010).
160 Having no history of a tuberculosis (TB) diagnosis significantly increased the odds of not using ART
161 (OR=5.30, 95%CI: 2.55-11.01, p<0.001). However, these variables were not determined to be significant
162 in the multivariable models.

163 Adjusting for age (and other known covariates) in the reduced multivariable model, non-use of ART in
164 men was associated with high risk of alcohol abuse (adjusted odds ratio (AOR)=3.68, 95%CI: 1.03-13.23,
165 p=0.046), being a widower compared to being unmarried (AOR=6.99, 95%CI: 1.46-33.42, p=0.020), and
166 having drug-resistant HIV (AOR=28.12, 95%CI: 13.89-56.94, p<0.001). Being in the Indian/white race
167 group decreased the likelihood of ART non-use (AOR=0.21, 95%CI: 0.06-0.84, p=0.027).

168 The reduced multivariable model showed older age to be a significant predictor of ART use, with an AOR
169 of 0.67 per year increase over the age of 38 years (AOR=0.67, 95%CI: 0.47-0.96, p=0.030) for non-use of
170 ART. Residence in rural tribal localities compared to urban localities (AOR=0.38, 95%CI: 0.18-0.78,

171 p=0.010) and having a co-morbidity such as diabetes or cardiac disease (AOR=0.06, 95%CI: 0.03-0.14,
172 p<0.001) were positively associated with ART use. Similarly, having two or more comorbidities reduced
173 the adjusted odds of ART non-use by 0.04 (95% CI: 0.01-0.13, p-value <0.001) as compared to having no
174 comorbidities.

175 Age, number of comorbidities, race, type of locality and HIV drug resistance remained statistically
176 significant across the univariate, saturated, and reduced logistic regression models. High risk of alcohol
177 abuse (AUDIT score of 16 or more) became significant in the reduced and saturated models but was not
178 found in the univariate model. Being a widower gained statistical significance in the reduced model only.

179 The saturated model significantly reduced the cohort's size due to missingness in some key independent
180 predictors, such as lifetime sexual partners and demonstrated basic understanding of HIV treatment
181 principles, that were being studied. This resulted in some variables being excluded in the reduced logistic
182 regression model based on missingness. The reduced model, controlling for a number of predictors
183 simultaneously, was selected based on AIC, Cragg-Uhler and McFadden pseudo-R² model fit parameters.
184 Previous history of a TB diagnosis, education level obtained, time since previous health visit did not
185 improve the model fit criteria. The reduced model's AIC was 413.1, McFadden and Cragg-Uhler's
186 pseudo-R² was 0.51 and 0.68 respectively.

Table 2: Factors associated with ART non-use among men aged ≥15 years, 2017 SABSSM V survey.

	Univariate Model	Saturated Multivariable Model	Reduced Multivariable Model
	<i>OR (95%CI) p-value</i>	<i>aOR (95%CI) p-value</i>	<i>aOR (95%CI) p-value</i>
Age (years)	0.51 (0.41-0.62) <0.001	0.41 (0.24-0.69) <0.001	0.67 (0.47-0.96) 0.030
Locality type of residence			
Urban	<i>1 (reference)</i>	<i>1 (reference)</i>	<i>1 (reference)</i>
Tribal Rural	0.54 (0.35-0.84) 0.010	0.26 (0.09-0.72) 0.010	0.38 (0.18 0.78) 0.010
Farm Rural	1.46 (0.83-2.59) 0.190	0.47 (0.07-3.16) 0.440	0.83 (0.30-2.30) 0.720
Race			
Black African	<i>1 (reference)</i>	<i>1 (reference)</i>	<i>1 (reference)</i>
Coloured	1.74 (0.87-3.48) 0.120	0.45 (0.04-4.99) 0.510	1.41 (0.41-4.67) 0.610
Indian/White	0.33 (0.12-0.91) 0.030	0.07 (0.005-0.978) 0.049	0.21 (0.06-0.84) 0.027
Marital Status			
Never Married	<i>1 (reference)</i>	<i>1 (reference)</i>	<i>1 (reference)</i>
Married	0.63 (0.38-1.02) 0.060	2.94 (0.75-11.48) 0.120	2.24 (0.873-5.73)0.090
Divorced / separated	0.38 (0.10-1.46) 0.160	3.08 (0.58-16.40) 0.190	0.56 (0.14-2.28) 0.423
Widower	0.84 (0.26-2.70) 0.780	11.11 (0.29-424.52) 0.200	6.99 (1.46-33.42) 0.020
Employment Status = Employed	0.56 (0.37-0.83) <0.001	0.49 (0.18-1.32) 0.160	0.78 (0.38-1.62) 0.510
Number of comorbidities			
No comorbidities	<i>1 (reference)</i>	<i>1 (reference)</i>	<i>1 (reference)</i>
One Comorbidity	0.15 (0.09-0.25) <0.001	0.10 (0.03-0.29) <0.001	0.06 (0.03-0.14) <0.001
Two or More Comorbidities	0.09 (0.03-0.23) <0.001	0.13 (0.02-0.73) 0.020	0.04 (0.01-0.13) <0.001
High probability of Alcohol Abuse			
High probability of Alcohol abuse	1.60 (0.71-1.13) 0.260	4.43 (1.27 -15.47) 0.020	3.68 (1.03-13.23) 0.046
HIV drug resistance			
Present	17.45 (10.02-30.39) <0.001	30.40 (10.01-92.32) <0.001	28.12 (13.89-56.94) <0.001
Presence of a Disability:			
Disability present	0.22 (0.07-0.68) 0.010	0.11 (0.01-1.08) 0.060	0.16 (0.02-1.11) 0.064
Level of Education Achieved			
No Education	<i>1 (reference)</i>	<i>1 (reference)</i>	
Completed Primary School	1.10 (0.46-2.63) 0.830	0.71 (0.14-3.70) 0.690	

Completed Grade 8-11	1.55 (0.68-3.52) 0.290	0.59 (0.14-2.47) 0.470	
Completed Matric or Higher Education	2.01 (0.85-4.73) 0.110	0.81 (0.15-4.44) 0.810	
Perception of participant's own health			
Excellent	<i>1 (reference)</i>	<i>1 (reference)</i>	
Good	0.93 (0.56-1.55) 0.790	2.81 (0.76-10.43) 0.120	
Fair	0.37 (0.19-0.70) <0.001	2.61 (0.56-12.26) 0.220	
Poor	0.42 (0.14-1.31) 0.140	0.72 (0.04-13.02) 0.820	
Participant's time since previous health visit			
Within the past six months	<i>1 (reference)</i>	<i>1 (reference)</i>	
More than six months but not more than a year ago	2.14 (1.18-3.88) 0.010	1.52 (0.43-5.36) 0.510	
More than one year ago	3.18 (1.87-5.39) <0.001	0.47 (0.10-2.26) 0.350	
Never	2.45 (1.25-4.83) 0.010	0.84 (0.17-4.28) 0.840	
Participant's main source of health care			
Government	<i>1 (reference)</i>	<i>1 (reference)</i>	
Private	1.03 (0.53-2.00) 0.920	1.22 (0.08-19.21) 0.890	
Other	2.84 (0.64-12.58) 0.170	3.19 (0.06-179.46) 0.570	
Previous TB diagnosis			
No previous diagnosis	5.30 (2.55-11.01) <0.001	2.82 (0.53-14.88) 0.220	
Participant has a history of drug use			
Participant admits to using drugs	0.78 (0.46-1.32) 0.360	0.93 (0.32-2.72) 0.900	
Previous sexually transmitted infection			
Has had a previous STI	1.41 (0.63-3.16) 0.400	1.25 (0.21-7.36) 0.810	
Demonstrated understanding of HIV prevention			
Has demonstrated a basic understanding	1.07 (0.70-1.63) 0.750	0.67 (0.24-1.87) 0.450	
Demonstrated understanding of HIV treatment			
Has demonstrated a basic understanding	0.33 (0.19-0.56) <0.001	0.47 (0.08-2.78) 0.400	
Exhibits stigma towards HIV positive individuals			
Exhibited Stigma towards HIV positive people	1.12 (0.75-1.68) 0.570	1.27 (0.52-3.10) 0.600	

187 Table 2 includes the univariate and multivariable logistic regression (saturated and reduced) models of factors associated with non-use of ART. Odds ratios, confidence intervals,
188 and p-values are listed for the univariate model. Adjusted odds ratios, confidence intervals, and p-values are listed for the multivariable models.
189 Abbreviations: A/OR – adjusted/odds ratio; ART – Antiretroviral therapy; SABSSM – South Africa National HIV Prevalence, Incidence, Behavior and Communication survey;
190 TB – tuberculosis.

191 **Discussion**

192 The UNAIDS 95–95–95 targets aim to ensure that 95% of people diagnosed with HIV are receiving
193 sustained antiretroviral treatment. However, more than 42% of men living with HIV were not on ART at
194 the time of data collection for this study. In this analysis ART use was higher among men above 38 years
195 old, men in tribal rural areas compared to urban areas, and men with at least one previously known
196 comorbidity. Non-use of ART in men was seen with high-risk alcohol use and was strongly associated
197 with HIV drug resistance.

198 Men generally delay engaging with healthcare until their health has deteriorated severely [9]. The reasons
199 for delay are largely related to how men internalize and deploy, within their lives and contexts, concepts
200 of masculinity. Other reasons include lack of time to seek care (due to prioritizing earning and providing
201 for families) or opting/feeling compelled to spend resources on basic requirements other than health [16].
202 However, this analysis found that men living with HIV with comorbidities are more likely to take up
203 ART than those without known comorbidities. This may be because men with comorbidities are already
204 familiar with healthcare facilities or have developed rapport with providers by seeking care for other
205 conditions – which in turn impacts their behavior related to ART initiation and continuation. Co-
206 morbidities can exacerbate or threaten to exacerbate experience of illness, and thus can serve to compel
207 earlier engagement with healthcare. Further investigation and qualitative studies are needed to explore
208 such hypotheses.

209 The positive association of ART use with increasing age aligns with findings regarding behavioral and
210 biological indicators for HIV where younger age is generally associated with a higher viral load [17],
211 which is a proxy for poor linkage to and uptake of care. The SABSSM V study also reported higher
212 undiagnosed HIV but also comparatively lower HIV prevalence in younger age groups of men [1].
213 Modelling estimates for 2021 show HIV prevalence in men peaking in middle-aged (aged 35-44 years
214 old), and an epidemiological shift of the burden to older men annually [3].

215 Barriers to accessing health services among young people are well-documented in the literature, and
216 include prohibitive societal values [18-21], judgmental attitudes of health workers, limited access to
217 relevant information, transport costs, and unsuitable facility operating hours [22-24]. Comparatively, older
218 people are likely to have stable or wider social networks including larger and more elaborate family ties,
219 facilitating financial or moral support to their engagement with healthcare [25]. Younger men are also
220 more likely to engage in risky socialization activities that include or involve substance use. A qualitative
221 study found a dominant pattern of decreasing binge and frequent drinking as men reached middle-age
222 which was precipitated by family-building, reductions in drinking with work colleagues, and health
223 concerns [25].

224 The present analysis also found a significant association between high-risk alcohol abuse and non-uptake
225 of ART among other poor health outcomes, which is consistent with existing literature regarding alcohol
226 and substances use and engagement with healthcare [9,17]. Alcohol and substance use are well
227 documented as barriers to ART uptake [26], especially among younger men who tend to demonstrate
228 ‘masculine bravado’, as part of assimilating to social groups or fitting in to society. This goes hand in
229 hand with demonstrating invulnerability and repudiation of the stigmatized ‘unwell’ image [9,16,27].

230 The current analysis found that men residing in tribal informal areas were more likely to be on ART. A
231 similar finding is reported from an analysis of the association between ART adherence and mental
232 distress in South Africa, where PLHIV in rural/traditional localities were more likely to be adherent
233 compared to those in urban areas [12]. Rural tribal areas had the highest response rate to the survey and
234 demand for circumcision among adult men, but also the lowest in HIV testing, accurate HIV knowledge,
235 and self-perceived ability to avoid HIV infection [1]. This makes the picture for rural settings complex
236 and calls for a more in-depth analysis.

237 The demarcation ‘rural’ in South Africa is considered fluid and may vary across the country, thus its
238 broad usage alongside ‘urban’ may mask finer patterns [28]. Provinces with large urban areas generally
239 fare better in health outcomes including maternal mortality ratio, infant mortality rate, TB cure rates, and

240 HIV burden [1] but also tend to have higher migration and mobility. Conversely, poorer health outcomes
241 in rural areas are attributed to socio-economic indicators that include low education level, poor sanitation
242 and unavailability of potable water, low household incomes, and food insecurity [27]. People in rural
243 areas generally depend on public healthcare facilities, which typically are distant, and have limited staff,
244 equipment, and packages of care [29]. Higher ART use in this analysis could be explained by the fact that
245 informal tribal settings typically contain networks with more intimate connections and ties of community
246 kinship, which may improve the rapport between patients and healthcare providers where more personal
247 relationships have been established [30].

248 The finding that Indian and White populations were more likely to be on ART is consistent with HIV
249 rates reported for these racial groups compared to Black Africans and Coloreds [1]. Race groups in South
250 Africa tend to use different health sectors [31], and challenges with public healthcare services can be
251 traceable to the segregationist policies of *apartheid* [32]. Since the end of *apartheid*, more doctors shifted
252 to the private sector which limits access and affordability of care. Considering that various socio-
253 economic advantages and vulnerabilities are conferred by race, these contextual and structural challenges
254 affect ART utilization.

255 Aspects of social organization, including relative absence of anonymity, have significance where studies
256 have illuminated concerns that providers routinely disclose health details of clients publicly in the
257 community [33]. Not only do such actions restate the power imbalance between providers/healthcare
258 systems and patients [34-35]; they also potentially drive HIV stigma. Studies from Southern Africa, for
259 instance, report on patients not initiating HIV treatment due to the stigma of being witnessed using local
260 clinics [36], or men being conscious of being labelled for using primary care facilities, which are held to
261 be feminine spaces [37]. Substantial investment in the public HIV programs in South Africa could be
262 instrumental in how the public healthcare system manages HIV care more efficiently. Increasing access to
263 multi-month dispensing (MMD) of ART and using differentiated models of HIV care (DMOC) can

264 minimize congestion in ART facilities and provide tailored ART care to support treatment continuity in
265 men while reducing stigma and barriers to care [38].

266 Of great concern, this analysis found unacceptably high levels of drug resistance in men with ART non-
267 use which may indicate ongoing transmission of drug resistant strains. As previously published, the
268 SABSSM V survey found HIVDR mutations in 29.4% of males aged 15-49 years [39]. Resistance was
269 detected in 27.4% of samples sequenced from virally unsuppressed respondents, and was most prevalent
270 in samples from respondents with prior exposure to ART but no ARVs detected at the time of the survey
271 [39]. Detecting this level of drug resistance is critical to ensuring that the ART regimens in use are
272 optimal for the population. Dolutegravir-based regimens were not in use at the time of the SABSSM V
273 survey, and these findings reinforce how critical the Tenofovir, Lamivudine, and Dolutegravir (TLD)
274 transition continues to be. This underscores the importance of ART optimization and ensuring treatment
275 adherence is strengthened among PLHIV. Men who have not initiated or have discontinued ART could be
276 considered a priority population for initiation (or re-initiation) of optimized ART regimens to ensure that
277 further resistance does not develop or spread, and a higher proportion of PLHIV are able to achieve viral
278 suppression.

279 Given that Dolutegravir-based regimens (with a higher genetic barrier to resistance than non-nucleoside
280 reverse transcriptase inhibitor (NNRTI)-based regimens) are now more widely used, findings from
281 SABSSM VI and other population studies will be informative in terms of better understanding the
282 prevalence of integrase inhibitor (INSTI) drug resistant mutations among ART patients who are virally
283 unsuppressed.

284 ***Limitations***

285 Neither ART adherence nor the length of time an individual has been on ARVs were considered in this
286 analysis. ART adherence was self-reported by participants, but these data were not used in this analysis
287 due to possible social desirability bias. ART use was determined by ARVs detected in the blood specimen

288 collected at the time of the survey, and detection is affected by the half-life of the medication of interest,
289 where adherence is suboptimal. The number of participants included in the *ARV undetected* cohort who
290 may have been unaware of their HIV status was not taken into account for this analysis. Some variables
291 had to be discarded in the multivariable models due to the large reduction in the dataset's size due to
292 missingness, despite the univariate analysis finding of significant associations with the outcome variable.

293

294 **Conclusions**

295 Trends of gender disparities in HIV program participation in the southern African region require further
296 study. Analyzing comparable survey data across the region allows for an evaluation of possible obstacles
297 that discourage men from participating in HIV programming and retention of care. Further insights are
298 needed as to which factors are at play that encourage or act as barriers to treatment for men, but not for
299 women.

300 Similar to antenatal and prevention of mother-to-child transmission (PMTCT) programs which have
301 helped in initiating women on ART, there should be greater social investment in initiatives that solely
302 target men. Identifying and adapting such interventions that can be effective at linking men to ART and
303 improve knowledge about HIV treatment, will help reduce the national burden of disease and enable
304 South Africa, a country with disproportional burden of infection, to finally reach epidemiological control.

305

306 **Acknowledgement**

307 The authors would like give thanks and acknowledgement to the entire SABSSM V field staff team, the
308 field supervisors, the nurses, and the data collectors who worked tirelessly to conduct this survey.

309

310 **Funding**

311 This project was supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the
312 Centers for Disease Control and Prevention (CDC) under the terms of cooperative agreement
313 NU2GGH001629. This publication was supported by cooperative agreement NU2GGH002093 from the
314 Centers for Disease Control and Prevention and the Public Health Institute.

315

316 **Disclaimer**

317 The findings and conclusions in this manuscript are those of the authors and do not necessarily represent
318 the official position of the funding agencies.

References

1. Simbayi LC, Zuma K, Zungu N, Moyo S, Marinda E, Jooste S, Mabaso M, Ramlagan S, North A, Van Zyl J, Mohlabane N. South African National HIV prevalence, incidence, behaviour and communication survey, 2017: Towards achieving the UNAIDS 90-90-90 targets. Cape Town: HSRC Press; 2019.
2. UNAIDS (2020). Country factsheets, South Africa.
3. Johnson L & Dorrington R. Thembisa version 4.4: A model for evaluating the impact of HIV/AIDS in South Africa. Cape Town: University of Cape Town; 2021. In
4. Brown LB, Getahun M, Ayieko J, Kwarisiima D, Owaraganise A, Atukunda M, Olilo W, Clark T, Bukusi EA, Cohen CR, Kanya MR. Factors predictive of successful retention in care among HIV-infected men in a universal test-and-treat setting in Uganda and Kenya: A mixed methods analysis. *PloS one*. 2019 Jan 23;14(1):e0210126. <https://doi.org/10.1371/journal.pone.0210126>
5. Adeyeye AO, Stirratt MJ, Burns DN. Engaging men in HIV treatment and prevention. *Lancet* (London, England). 2018 Dec 1;392(10162):2334-5. [https://doi:10.1016/S0140-6736\(18\)32994-5](https://doi:10.1016/S0140-6736(18)32994-5)
6. Mukumbang FC. Leaving no man behind: how differentiated service delivery models increase men's engagement in HIV care. *International Journal of Health Policy and Management*. 2021 Mar;10(3):129. <https://doi:10.34172/ijhpm.2020.32>
7. Staveteig S, Croft TN, Kampa KT, Head SK. Reaching the 'first 90': Gaps in coverage of HIV testing among people living with HIV in 16 African countries. *PloS one*. 2017 Oct 12;12(10):e0186316. <https://doi:10.1371/journal.pone.0186316>
8. Lessells RJ, Mutevedzi PC, Cooke GS, Newell ML. Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural KwaZulu-Natal, South Africa. *JAIDS Journal of Acquired*

Immune Deficiency Syndromes. 2011 Mar 1;56(3):e79-86.

<https://doi.org/10.1097/QAI.0b013e3182075ae2>

9. Chikovore J, Hart G, Kumwenda M, Chipungu GA, Desmond N, Corbett L. Control, struggle, and emergent masculinities: a qualitative study of men's care-seeking determinants for chronic cough and tuberculosis symptoms in Blantyre, Malawi. *BMC public health*. 2014 Dec;14(1):1-2. <https://doi.org/10.1186/1471-2458-14-1053>
10. Nardell MF, Adeoti O, Peters C, Kakuhikire B, Govathson-Mandimika C, Long L, Pascoe S, Tsai AC, Katz IT. Men missing from the HIV care continuum in sub-Saharan Africa: a meta-analysis and meta-synthesis. *Journal of the International AIDS Society*. 2022 Mar;25(3):e25889. <https://doi.org/10.1002/jia2.25889>
11. Sileo KM, Simbayi LC, Abrams A, Cloete A, Kiene SM. The role of alcohol use in antiretroviral adherence among individuals living with HIV in South Africa: event-level findings from a daily diary study. *Drug and alcohol dependence*. 2016 Oct 1;167:103-11. <https://doi.org/10.1016/j.drugalcdep.2016.07.028>
12. Marinda E, Zungu N, Chikovore J, Mthembu J, Magampa M, Mathentamo Q, Nwosu CO, Maoba P, Ramlagan S, Zuma K, Moyo S. Association between ART adherence and mental health: results from a national HIV sero-behavioural survey in South Africa. *AIDS and Behavior*. 2021 Oct 23:1-3. <https://doi.org/10.1007/s10461-021-03505-4>
13. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. AUDIT: The alcohol use disorders identification test: Guidelines for use in primary health care. World Health Organization; 2001.
14. Team, R. C. (2021). R: A Language and Environment for Statistical Computing. *R 4.1.2*. Vienna, Austria: R Foundation for Statistical Computing. Retrieved from <https://www.R-project.org/>
15. Lumley, T. (2020). "survey: analysis of complex survey samples". *R package version 4.0*.
16. Chikovore J, Hart G, Kumwenda M, Chipungu GA, Corbett L. 'For a mere cough, men must just chew Conjex, gain strength, and continue working': the provider construction and tuberculosis care-seeking implications in Blantyre, Malawi. *Global health action*. 2015 Dec 1;8(1):26292. <https://doi.org/10.3402/gha.v8.26292>
17. Amirkhanian YA, Kelly JA, DiFranceisco WJ, Kuznetsova AV, Tarima SS, Yakovlev AA, Musatov VB. Predictors of HIV care engagement, antiretroviral medication adherence, and viral suppression among people living with HIV infection in St. Petersburg, Russia. *AIDS and Behavior*. 2018 Mar;22:791-9. <https://doi.org/10.1007/s10461-016-1638-9>
18. Chikovore J, Nystrom L, Lindmark G, Ahlberg BM. Denial and violence: Paradoxes in men's perspectives to premarital sex and pregnancy in Rural Zimbabwe. *African Sociological Review/Revue Africaine de Sociologie*. 2003;7(1):53-72.
19. Chikovore J, Nystrom L, Lindmark G, Ahlberg BM. HIV/AIDS and sexuality: concerns of youths in rural Zimbabwe. *African Journal of AIDS Research*. 2009 Dec 1;8(4):503-13. <https://doi.org/10.2989/AJAR.2009.8.4.14.1051>
20. Chikovore J, Nystrom L, Lindmark G, Ahlberg BM. "How can I gain skills if I Don't practice?" the dynamics of prohibitive silence against pre-marital pregnancy and sex in Zimbabwe. *PloS one*. 2013 Jan 23;8(1):e53058. <https://doi.org/10.1371/journal.pone.0053058>

21. Waling A, Farrugia A, Fraser S. Embarrassment, shame, and reassurance: Emotion and young people's access to online sexual health information. *Sexuality Research and Social Policy*. 2022 Jan 10:1-3. <https://doi.org/10.1007/s13178-021-00668-6>
22. Mokomane Z, Mokhele T, Mathews C, Makoae M. Availability and accessibility of public health services for adolescents and young people in South Africa. *Children and Youth Services Review*. 2017 Mar 1;74:125-32. <https://doi.org/10.1016/j.childyouth.2017.02.001>
23. Ngwenya N, Nkosi B, Mchunu LS, Ferguson J, Seeley J, Doyle AM. Behavioural and socio-ecological factors that influence access and utilisation of health services by young people living in rural KwaZulu-Natal, South Africa: Implications for intervention. *PloS one*. 2020 Apr 14;15(4):e0231080. <https://doi.org/10.1371/journal.pone.0231080>
24. Nkosi B, Seeley J, Ngwenya N, Mchunu SL, Gumede D, Ferguson J, Doyle AM. Exploring adolescents and young people's candidacy for utilising health services in a rural district, South Africa. *BMC health services research*. 2019 Dec;19(1):1-2. <https://doi.org/10.1186/s12913-019-3960-1>
25. Keenan K, Saburova L, Bobrova N, Elbourne D, Ashwin S, Leon DA. Social factors influencing Russian male alcohol use over the life course: a qualitative study investigating age based social norms, masculinity, and workplace context. *PloS one*. 2015 Nov 17;10(11):e0142993. <https://doi.org/10.1371/journal.pone.0142993>
26. Puryear SB, Balzer LB, Ayieko J, Kwarisiima D, Hahn JA, Charlebois ED, Clark TD, Cohen CR, Bukusi EA, Kanya MR. (2020). Associations between alcohol use and HIV care cascade outcomes among adults undergoing population-based HIV testing in East Africa. *AIDS (London, England)*. 2020 Mar 3;34(3):405. <https://doi.org/10.1097%2FQAD.0000000000002427>
27. Thurnell-Read T. Masculinity, age and rapport in qualitative research. In *Gender identity and research relationships* 2016 May 10 (Vol. 14, pp. 23-41). Emerald Group Publishing Limited.
28. Gaede B, Versteeg M. The state of the right to health in rural South Africa. *South African health review*. 2011 Jan 1;2011(1):99-106. <https://doi.org/10.10520/EJC119080>
29. Harris B, Goudge J, Ataguba JE, McIntyre D, Nxumalo N, Jikwana S, Chersich M. Inequities in access to health care in South Africa. *Journal of public health policy*. 2011 Jun 1;32:S102-23.
30. Rockenbauch T, Sakdapolrak P. Social networks and the resilience of rural communities in the Global South: a critical review and conceptual reflections. *Ecology and Society*. 2017 Mar 1;22(1).
31. Mhlanga D, Garidzirai R. The influence of racial differences in the demand for healthcare in South Africa: A case of public healthcare. *International journal of environmental research and public health*. 2020 Jul;17(14):5043. <https://doi.org/10.3390/ijerph17145043>
32. Bell GJ, Ncayiyana J, Sholomon A, Goel V, Zuma K, Emch M. Race, place, and HIV: The legacies of apartheid and racist policy in South Africa. *Social Science & Medicine*. 2022 Mar 1;296:114755. <https://doi.org/10.1016/j.socscimed.2022.114755>

33. Kumwenda M, Desmond N, Hart G, Choko A, Chipungu GA, Nyirenda D, Shand T, Corbett EL, Chikovore J. Treatment-seeking for tuberculosis-suggestive symptoms: a reflection on the role of human agency in the context of universal health coverage in Malawi. *PloS one*. 2016 Apr 21;11(4):e0154103. <https://doi.org/10.1371/journal.pone.0154103>
34. Nimmon L, Stenfors-Hayes T. The “Handling” of power in the physician-patient encounter: perceptions from experienced physicians. *BMC medical education*. 2016 Dec;16:1-9. <https://doi.org/10.1186/s12909-016-0634-0>
35. Goodyear-Smith F, Buetow S. Power issues in the doctor-patient relationship. *Health care analysis*. 2001 Dec;9:449-62. <https://doi.org/10.1023/A:1013812802937>
36. Chimoyi L, Chikovore J, Musenge E, Mabuto T, Chetty-Makkan CM, Munyai R, Nchachi T, Charalambous S, Setswe G. Understanding factors influencing utilization of HIV prevention and treatment services among patients and providers in a heterogeneous setting: a qualitative study from South Africa. *PLoS Global Public Health*. 2022 Feb 3;2(2):e0000132. <https://doi.org/10.1371/journal.pgph.0000132>
37. Mavhu W, Dauya E, Bandason T, Munyati S, Cowan FM, Hart G, Corbett EL, Chikovore J. Chronic cough and its association with TB–HIV co-infection: factors affecting help-seeking behaviour in Harare, Zimbabwe. *Tropical Medicine & International Health*. 2010 May;15(5):574-9. <https://doi.org/10.1111/j.1365-3156.2010.02493.x>
38. Bailey LE, Siberry GK, Agaba P, Douglas M, Clinkscapes JR, Godfrey C. The impact of COVID-19 on multi-month dispensing (MMD) policies for antiretroviral therapy (ART) and MMD uptake in 21 PEPFAR-supported countries: a multi-country analysis. *Journal of the International AIDS Society*. 2021 Oct;24:e25794. <https://doi.org/10.1002/jia2.25794>
39. Moyo S, Hunt G, Zuma K, Zungu M, Marinda E, Mabaso M, Kana V, Kalimashe M, Ledwaba J, Naidoo I, Takatshana S. HIV drug resistance profile in South Africa: findings and implications from the 2017 national HIV household survey. *PLoS One*. 2020 Nov 4;15(11):e0241071. <https://doi.org/10.1371/journal.pone.0241071>

Figure 1: Study Sample Flow Diagram, SABBSM V survey, 2017




Figure 1